Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Intra vs Inter Cross-Resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer.

Lombard AP, Liu L, Cucchiara V, Liu C, Armstrong CM, Zhao R, Yang JC, Lou W, Evans CP, Gao AC.

Mol Cancer Ther. 2018 Jun 11. pii: molcanther.1269.2017. doi: 10.1158/1535-7163.MCT-17-1269. [Epub ahead of print]

PMID:
29891490
2.

Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone metastatic prostate cancer.

Zhao J, Sun G, Liao B, Zhang X, Armstrong CM, Yin X, Liu J, Chen J, Yang Y, Zhao P, Tang Q, Wang Z, Chen Z, Li X, Wei Q, Li X, Chen N, Gao AC, Shen P, Zeng H.

BJU Int. 2018 May 17. doi: 10.1111/bju.14398. [Epub ahead of print]

PMID:
29772102
3.

Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.

Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV.

Eur Urol. 2018 May;73(5):715-723. doi: 10.1016/j.eururo.2017.11.038. Epub 2017 Dec 16.

PMID:
29258679
4.

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.

Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx118.

PMID:
29206995
5.

Quercetin Targets hnRNPA1 to Overcome Enzalutamide Resistance in Prostate Cancer Cells.

Tummala R, Lou W, Gao AC, Nadiminty N.

Mol Cancer Ther. 2017 Dec;16(12):2770-2779. doi: 10.1158/1535-7163.MCT-17-0030. Epub 2017 Jul 20.

PMID:
28729398
6.

ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.

Lombard AP, Liu C, Armstrong CM, Cucchiara V, Gu X, Lou W, Evans CP, Gao AC.

Mol Cancer Ther. 2017 Oct;16(10):2257-2266. doi: 10.1158/1535-7163.MCT-17-0179. Epub 2017 Jul 11.

PMID:
28698198
7.

Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer.

Armstrong CM, Gao AC.

Asian J Urol. 2016 Oct;3(4):185-194. doi: 10.1016/j.ajur.2016.08.001. Epub 2016 Aug 22.

8.

Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.

Liu C, Armstrong CM, Lou W, Lombard AP, Cucchiara V, Gu X, Yang JC, Nadiminty N, Pan CX, Evans CP, Gao AC.

Mol Cancer Ther. 2017 Aug;16(8):1521-1530. doi: 10.1158/1535-7163.MCT-16-0912. Epub 2017 May 12.

PMID:
28500234
9.

MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.

Armstrong CM, Liu C, Lou W, Lombard AP, Evans CP, Gao AC.

Prostate. 2017 Jun;77(9):1020-1028. doi: 10.1002/pros.23358.

10.

Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.

Recouvreux MV, Wu JB, Gao AC, Zonis S, Chesnokova V, Bhowmick N, Chung LW, Melmed S.

Endocrinology. 2017 Jul 1;158(7):2255-2268. doi: 10.1210/en.2016-1939.

PMID:
28444169
11.

Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy.

Cucchiara V, Yang JC, Mirone V, Gao AC, Rosenfeld MG, Evans CP.

Cancers (Basel). 2017 Jan 16;9(1). pii: E9. doi: 10.3390/cancers9010009. Review.

12.

CCN3-EZH2-AR feedback loop: new targets for enzalutamide and castration resistant prostate cancer.

Armstrong CM, Gao AC.

J Cell Commun Signal. 2017 Mar;11(1):89-91. doi: 10.1007/s12079-017-0378-6. Epub 2017 Mar 2.

13.

Induction of neuroendocrine differentiation in castration resistant prostate cancer cells by adipocyte differentiation-related protein (ADRP) delivered by exosomes.

Lin LC, Gao AC, Lai CH, Hsieh JT, Lin H.

Cancer Lett. 2017 Apr 10;391:74-82. doi: 10.1016/j.canlet.2017.01.018. Epub 2017 Jan 18.

PMID:
28109910
14.

Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.

Liu C, Armstrong CM, Lou W, Lombard A, Evans CP, Gao AC.

Mol Cancer Ther. 2017 Jan;16(1):35-44. doi: 10.1158/1535-7163.MCT-16-0186. Epub 2016 Oct 28.

15.

Corrigendum: ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer.

Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, Xiang Q, Yang JC, Louie MC, Borowsky AD, Gao AC, Evans CP, Lam KS, Xu J, Kung HJ, Evans RM, Xu Y, Chen HW.

Nat Med. 2016 Jun 7;22(6):692. doi: 10.1038/nm0616-692b. No abstract available.

PMID:
27270780
16.

Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.

Liu C, Armstrong C, Zhu Y, Lou W, Gao AC.

Oncotarget. 2016 May 31;7(22):32210-20. doi: 10.18632/oncotarget.8493.

17.

ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer.

Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, Xiang Q, Yang JC, Louie MC, Borowsky AD, Gao AC, Evans CP, Lam KS, Xu J, Kung HJ, Evans RM, Xu Y, Chen HW.

Nat Med. 2016 May;22(5):488-96. doi: 10.1038/nm.4070. Epub 2016 Mar 28. Erratum in: Nat Med. 2016 Jun 7;22(6):692.

18.

Mechanisms of resistance in castration-resistant prostate cancer (CRPC).

Chandrasekar T, Yang JC, Gao AC, Evans CP.

Transl Androl Urol. 2015 Jun;4(3):365-80. doi: 10.3978/j.issn.2223-4683.2015.05.02. Review.

19.

Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation.

Tummala R, Nadiminty N, Lou W, Evans CP, Gao AC.

Prostate. 2016 Apr;76(5):445-55. doi: 10.1002/pros.23134. Epub 2015 Dec 30.

20.

Targeting molecular resistance in castration-resistant prostate cancer.

Chandrasekar T, Yang JC, Gao AC, Evans CP.

BMC Med. 2015 Sep 1;13:206. doi: 10.1186/s12916-015-0457-6. Review.

21.

Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies.

Armstrong CM, Gao AC.

Am J Clin Exp Urol. 2015 Aug 8;3(2):64-76. eCollection 2015. Review.

22.

Stat5a/b in Prostate Cancer Metastasis.

Gao AC, Zhu Y.

Am J Pathol. 2015 Sep;185(9):2351-3. doi: 10.1016/j.ajpath.2015.06.002. Epub 2015 Jul 15.

PMID:
26187549
23.

NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer.

Nadiminty N, Tummala R, Liu C, Lou W, Evans CP, Gao AC.

Mol Cancer Ther. 2015 Aug;14(8):1884-95. doi: 10.1158/1535-7163.MCT-14-1057. Epub 2015 Jun 8.

24.

Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.

Zhu Y, Liu C, Armstrong C, Lou W, Sandher A, Gao AC.

Clin Cancer Res. 2015 Sep 15;21(18):4133-42. doi: 10.1158/1078-0432.CCR-15-0269. Epub 2015 May 20.

25.

Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.

Liu C, Lou W, Armstrong C, Zhu Y, Evans CP, Gao AC.

Prostate. 2015 Sep;75(13):1341-53. doi: 10.1002/pros.23015. Epub 2015 May 13.

26.

Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.

Liu C, Lou W, Zhu Y, Yang JC, Nadiminty N, Gaikwad NW, Evans CP, Gao AC.

Cancer Res. 2015 Apr 1;75(7):1413-22. doi: 10.1158/0008-5472.CAN-14-3080. Epub 2015 Feb 3.

27.

Synthesis of carbon-11-labeled aminoalkylindole derivatives as new candidates of cannabinoid receptor radioligands for PET imaging of alcohol abuse.

Gao M, Gao AC, Wang M, Zheng QH.

Bioorg Med Chem Lett. 2014 Dec 15;24(24):5581-5586. doi: 10.1016/j.bmcl.2014.10.097. Epub 2014 Nov 6.

PMID:
25466179
28.

Zoledronic acid at the time of castration prevented castration-induced bone metastasis in mice.

Ghosh PM, Gao AC.

Endocr Relat Cancer. 2014 Oct;21(5):C11-4. doi: 10.1530/ERC-14-0387. Epub 2014 Sep 2.

29.

Simple synthesis of new carbon-11-labeled 1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives for PET imaging of A₃ adenosine receptor.

Gao M, Gao AC, Wang M, Zheng QH.

Appl Radiat Isot. 2014 Sep;91:71-8. doi: 10.1016/j.apradiso.2014.05.005. Epub 2014 May 21.

PMID:
24908190
30.

Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST).

Zhu Y, Liu C, Cui Y, Nadiminty N, Lou W, Gao AC.

Prostate. 2014 Aug;74(11):1086-94. doi: 10.1002/pros.22819. Epub 2014 May 12.

PMID:
24819501
31.

Expression, characterization, and improvement of a newly cloned halohydrin dehalogenase from Agrobacterium tumefaciens and its application in production of epichlorohydrin.

Liu ZQ, Gao AC, Wang YJ, Zheng YG, Shen YC.

J Ind Microbiol Biotechnol. 2014 Jul;41(7):1145-58. doi: 10.1007/s10295-014-1443-2. Epub 2014 Apr 29.

PMID:
24777710
32.

Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.

Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC.

Clin Cancer Res. 2014 Jun 15;20(12):3198-3210. doi: 10.1158/1078-0432.CCR-13-3296. Epub 2014 Apr 16. Erratum in: Clin Cancer Res. 2017 Jan 1;23 (1):323.

33.

Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model.

Nguyen HG, Yang JC, Kung HJ, Shi XB, Tilki D, Lara PN Jr, DeVere White RW, Gao AC, Evans CP.

Oncogene. 2014 Sep 4;33(36):4521-30. doi: 10.1038/onc.2014.25. Epub 2014 Mar 24.

34.

Upregulation of glucose metabolism by NF-κB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells.

Cui Y, Nadiminty N, Liu C, Lou W, Schwartz CT, Gao AC.

Endocr Relat Cancer. 2014 May 6;21(3):435-42. doi: 10.1530/ERC-14-0107. Print 2014 Jun.

35.

Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model.

Qu S, Wang K, Xue H, Wang Y, Wu R, Liu C, Gao AC, Gout PW, Collins CC, Wang Y.

Mol Oncol. 2014 Mar;8(2):311-22. doi: 10.1016/j.molonc.2013.12.004. Epub 2013 Dec 15.

36.

Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells.

Liu C, Zhu Y, Lou W, Cui Y, Evans CP, Gao AC.

Prostate. 2014 Feb;74(2):201-9. doi: 10.1002/pros.22741. Epub 2013 Oct 16.

37.

RhoGDIα downregulates androgen receptor signaling in prostate cancer cells.

Zhu Y, Liu C, Tummala R, Nadiminty N, Lou W, Gao AC.

Prostate. 2013 Nov;73(15):1614-22. doi: 10.1002/pros.22615. Epub 2013 Aug 6.

38.

Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer.

Zhu Y, Liu C, Nadiminty N, Lou W, Tummala R, Evans CP, Gao AC.

Mol Cancer Ther. 2013 Sep;12(9):1829-36. doi: 10.1158/1535-7163.MCT-13-0208. Epub 2013 Jul 16.

39.

Lin28 promotes growth of prostate cancer cells and activates the androgen receptor.

Tummala R, Nadiminty N, Lou W, Zhu Y, Gandour-Edwards R, Chen HW, Evans CP, Gao AC.

Am J Pathol. 2013 Jul;183(1):288-95. doi: 10.1016/j.ajpath.2013.03.011.

40.

NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants.

Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP, Gao AC.

Mol Cancer Ther. 2013 Aug;12(8):1629-37. doi: 10.1158/1535-7163.MCT-13-0027. Epub 2013 May 22.

41.

Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex.

Duan Z, Zou JX, Yang P, Wang Y, Borowsky AD, Gao AC, Chen HW.

Prostate. 2013 Apr;73(5):455-66. doi: 10.1002/pros.22587. Epub 2012 Oct 4.

PMID:
23038103
42.

Functional p53 determines docetaxel sensitivity in prostate cancer cells.

Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q, Shi XB, deVere White RW, Gao AC.

Prostate. 2013 Mar;73(4):418-27. doi: 10.1002/pros.22583. Epub 2012 Sep 19.

43.

Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.

Yang P, Guo L, Duan ZJ, Tepper CG, Xue L, Chen X, Kung HJ, Gao AC, Zou JX, Chen HW.

Mol Cell Biol. 2012 Aug;32(15):3121-31. doi: 10.1128/MCB.00204-12. Epub 2012 May 29.

44.

MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth.

Nadiminty N, Tummala R, Lou W, Zhu Y, Shi XB, Zou JX, Chen H, Zhang J, Chen X, Luo J, deVere White RW, Kung HJ, Evans CP, Gao AC.

PLoS One. 2012;7(3):e32832. doi: 10.1371/journal.pone.0032832. Epub 2012 Mar 30.

45.
46.

MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells.

Nadiminty N, Tummala R, Lou W, Zhu Y, Zhang J, Chen X, eVere White RW, Kung HJ, Evans CP, Gao AC.

J Biol Chem. 2012 Jan 6;287(2):1527-37. doi: 10.1074/jbc.M111.278705. Epub 2011 Nov 28.

47.

A proteomic approach to elucidate the multiple targets of selenium-induced cell-growth inhibition in human lung cancer.

Zhong X, Li L, Wang M, Luo W, Tan Q, Xu F, Zhu W, Wang Q, Wang T, Hou M, Nadimity N, Xue X, Chen J, Ma W, Gao AC, Zhou Q.

Thorac Cancer. 2011 Nov;2(4):164-178. doi: 10.1111/j.1759-7714.2011.00066.x.

PMID:
27755845
48.

Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives.

Nadiminty N, Gao AC.

World J Urol. 2012 Jun;30(3):287-95. doi: 10.1007/s00345-011-0771-3. Epub 2011 Oct 19. Review.

PMID:
22009116
49.

The interleukin 6 receptor is a direct transcriptional target of E2F3 in prostate tumor derived cells.

Libertini SJ, Chen H, al-Bataina B, Koilvaram T, George M, Gao AC, Mudryj M.

Prostate. 2012 May 1;72(6):649-60. doi: 10.1002/pros.21468. Epub 2011 Aug 11.

PMID:
21837779
50.

Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer.

Liu C, Nadiminty N, Tummala R, Chun JY, Lou W, Zhu Y, Sun M, Evans CP, Zhou Q, Gao AC.

Genes Cancer. 2011 Feb;2(2):151-9. doi: 10.1177/1947601911409744.

Supplemental Content

Support Center